ProCE Banner Activity

Collecting Real-World Data on HCV Treatment as Prevention in PWID: The Scottish Experience

Clinical Thought
The promising HCV treatment as prevention (TasP) model has yet to be proven in real-world PWID. Here, we share our experiences, progress, and remaining challenges with evaluating a local HCV TasP program in Tayside, Scotland.

Released: September 04, 2019

Expiration: September 02, 2020

No longer available for credit.

Share

Faculty

Christopher Byrne

Christopher Byrne, BA (Hons), MSc

School of Medicine
University of Dundee
Dundee, Scotland

John F. Dillon

John F. Dillon, MB BS, MRCP, MD, FRCP (Edin), FRCP (Lond)

Professor of Hepatology and Gastroenterology
Division of Molecular and Cellular Medcine
School of Medicine, University of Dundee
Honorary Consultant Physician, Gastroenterologist & Hepatologist
Clinical Lead for Blood Borne Viruses

NHS Tayside
NHS Research Scotland National Lead for Hepatology
President of Scottish Society of Gastroenterology
Dundee, United Kingdom

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Gilead

Partners

INHSU

ProCE Banner

Faculty Disclosure

Primary Author

Christopher Byrne, BA (Hons), MSc

School of Medicine
University of Dundee
Dundee, Scotland

Christopher Byrne, BA (Hons), MSc, has no relevant conflicts of interest to report.

John F. Dillon, MB BS, MRCP, MD, FRCP (Edin), FRCP (Lond)

Professor of Hepatology and Gastroenterology
Division of Molecular and Cellular Medcine
School of Medicine, University of Dundee
Honorary Consultant Physician, Gastroenterologist & Hepatologist
Clinical Lead for Blood Borne Viruses

NHS Tayside
NHS Research Scotland National Lead for Hepatology
President of Scottish Society of Gastroenterology
Dundee, United Kingdom

John F. Dillon, MB BS, MRCP, MD, FRCP (Edin), FRCP (Lond), has disclosed that he has received funds for research support and fees for non-CME/CE services from AbbVie, Gilead Sciences, Janssen, Merck, and Roche.